Literature DB >> 21507900

Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+.

Damien Toulorge1, Serge Guerreiro, Audrey Hild, Uwe Maskos, Etienne C Hirsch, Patrick P Michel.   

Abstract

Epidemiological and experimental evidence indicates that nicotine is protective for Parkinson disease vulnerable dopamine neurons, but the underlying mechanism of this effect remains only partly characterized. To address this question, we established rat midbrain cultures maintained in experimental conditions that favor the selective and spontaneous loss of dopamine neurons. We report here that nicotine afforded neuroprotection to dopamine neurons (EC(50)=0.32 μM) but only in a situation where cytosolic Ca(2+) (Ca(2+)(cyt)) was slightly and chronically elevated above control levels by concurrent depolarizing treatments. By a pharmacological approach, we demonstrated that the rise in Ca(2+)(cyt) was necessary to sensitize dopamine neurons to the action of nicotine through a mechanism involving α-bungarotoxin-sensitive (presumably α7) nicotinic acetylcholine receptors (nAChRs) and secondarily T-type voltage-gated calcium channels. Confirming the role played by α7 nAChRs in this effect, nicotine had no protective action in midbrain cultures prepared from genetically engineered mice lacking this receptor subtype. Signaling studies revealed that Ca(2+)(cyt) elevations evoked by nicotine and concomitant depolarizing treatments served to activate a survival pathway involving the calcium effector protein calmodulin and phosphatidylinositol 3-kinase. Collectively, our data support the idea that the protective action of nicotine for dopamine neurons is activity-dependent and gated by Ca(2+)(cyt).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21507900     DOI: 10.1096/fj.11-182824

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  34 in total

1.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

2.  Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.

Authors:  Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet
Journal:  Neurobiol Dis       Date:  2018-06-01       Impact factor: 5.996

3.  Boosting Endogenous Resistance of Brain to Ischemia.

Authors:  Fen Sun; Stephen R Johnson; Kunlin Jin; Victor V Uteshev
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

4.  Lynx1 supports neuronal health in the mouse dorsal striatum during aging: an ultrastructural investigation.

Authors:  Atsuko Kobayashi; Rell L Parker; Ashley P Wright; Hajer Brahem; Pauline Ku; Katherine M Oliver; Andreas Walz; Henry A Lester; Julie M Miwa
Journal:  J Mol Neurosci       Date:  2014-07-17       Impact factor: 3.444

5.  The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.

Authors:  Tanuja Bordia; Matthew McGregor; Roger L Papke; Michael W Decker; J Michael McIntosh; Maryka Quik
Journal:  Exp Neurol       Date:  2014-09-28       Impact factor: 5.330

6.  Identification and characterization of poly(I:C)-induced molecular responses attenuated by nicotine in mouse macrophages.

Authors:  Wen-Yan Cui; Shufang Zhao; Renata Polanowska-Grabowska; Ju Wang; Jinxue Wei; Bhagirathi Dash; Sulie L Chang; Jeffrey J Saucerman; Jun Gu; Ming D Li
Journal:  Mol Pharmacol       Date:  2012-10-01       Impact factor: 4.436

Review 7.  [Epidemiology and causes of Parkinson's disease].

Authors:  C M Lill; C Klein
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

8.  ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Danhui Zhang; Tanuja Bordia; Matthew McGregor; J Michael McIntosh; Michael W Decker; Maryka Quik
Journal:  Mov Disord       Date:  2014-02-11       Impact factor: 10.338

Review 9.  Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis.

Authors:  Cheng-Long Xie; Jia-Lin Pan; Su-Fang Zhang; Jing Gan; Zhen-Guo Liu
Journal:  Neurol Sci       Date:  2014-02-09       Impact factor: 3.307

Review 10.  Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease.

Authors:  Rahul Srinivasan; Brandon J Henderson; Henry A Lester; Christopher I Richards
Journal:  Pharmacol Res       Date:  2014-03-01       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.